Glycobia Inc. employs proprietary glycoengineering technology to design bacteria that directly produce human peptide and protein drugs. Many of today’s blockbuster biologic drugs are produced by culturing mammalian cells. This process is laborious, expensive and vulnerable to contamination with dangerous viruses. Glycobia has built a platform to produce the same drugs—or improved versions of such drugs—faster, cheaper, and more safely than current methods.
Glycobia’s glycoengineering approach enables a robust glycoprotein production solution for the biopharmaceutical industry and seeks to lessen the financial burden on health-care consumers.
Glycobia’s technology was invented at Cornell and founded by a Cornell faculty member and PhD alumnus.